Actively Recruiting
Phase 3 Study to Test the Effectiveness and Safety of HRS-5965 Capsules for Treating Primary IgA Nephropathy
Led by Chengdu Suncadia Medicine Co., Ltd. · Updated on 2025-08-05
378
Participants Needed
1
Research Sites
61 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of the HRS-5965 capsule for people with primary IgA nephropathy, a kidney condition confirmed by biopsy. This randomized, double-blind, placebo-controlled Phase III trial aims to compare HRS-5965 with a placebo to better understand its impact on this disease. Participants in this study will be assigned randomly to receive either the HRS-5965 capsule or a placebo. The study involves multiple centers and uses a parallel design where neither participants nor researchers know which treatment is given. Treatment effects will be assessed over time by measuring kidney function and protein levels in urine at specific time points. During the trial, participants will have assessments including 24-hour urine protein to creatinine ratios and estimated glomerular filtration rate eGFR at baseline, week 36, and week 104. Researchers will monitor changes in kidney function and protein excretion to evaluate treatment impact. The study is expected to run until December 2028 and includes safety monitoring throughout the participation period.
CONDITIONS
Brief Title
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Research Team
S
Sheng Qi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here